Classifications: immunomodulator; interleukin-1 receptor antagonist; Therapeutic: antirheumatic
Pregnancy Category: B
100 mg prefilled syringes
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1R1). It blocks the biologic activity of IL-1
by inhibiting it from binding to interleukin receptors that are present in both bone and cartilage as well as other kinds
of tissues. Interleukin-1 is produced in response to inflammation. IL-1 mediates various responses of tissues, including
inflammatory and immunologic responses.
Ana-kinra competes with interleukin-1 (IL-1) by inhibiting it from binding to its receptor sites in tissues.
Treatment of rheumatoid arthritis in patients failing other disease modifying antirheumatic drugs (DMARDs). Usually given
in combination with another DMARD.
Hypersensitivity to anakinra, E. coliderived products, latex; active infections; live vaccines.
Neutropenia, immunosuppressed patients, or patients with frequent, serious infections; asthmatics; elderly; renal impairment;
concomitant use of tumor necrosis factor blocking agents (TNF), etanercept, or infliximab; pregnancy (category B), lactation,
Route & Dosage
Adult: SC 100 mg daily
- Do not give anakinra if the patient has an active infection.
- Note that anakinra should not ordinarily be given with tumor necrosis factor (TNF) blocking agents.
- Discard any unused portions as the drug contains no preservative.
- Check expiration date and do not use if expired.
- Store in the refrigerator at 2° to 8° C (36° to 46° F). DO NOT FREEZE OR SHAKE. Protect from light.
Adverse Effects (≥1%)Body as a Whole: Bacterial infections
, flu, other
, abdominal pain. Hematologic:
count, antibody formation. Other: Injection site reactions (erythema, ecchymosis, edema, inflammation, pain).
Increased risk of infection
with live virus vaccine
, etanercept, infliximab.
Increased risk of neutropenia
as well as infection
95% absorbed SC site. Peak:
37 h. Elimination:
In urine. Half-Life:
Assessment & Drug Effects
- Monitor for S&S of infection (e.g., pneumonia or other URI, cellulitis). Withhold drug and notify physician if these appear.
- Lab tests: Monitor absolute neutrophil count (ANC) prior to initiating anakinra, monthly for 3 mo, and q3mo thereafter for
1 y; monitor periodically WBC and platelet counts.
- Monitor closely patients with impaired renal function for S&S of adverse drug reactions.
- Assess for injection site reactions manifested by erythema, ecchymosis, inflammation, and pain.
Patient & Family Education
- Review carefully the "Information for Patients and Caregivers" leaflet for detailed instructions on handling and
- Give the injection at approximately the same time every day.
- Administer only 1 dose (the entire contents of 1 prefilled glass syringe) per day. Discard any unused portions as the drug
contains no preservative. Do not save unused drug.
- Do not permit vaccination with live vaccines while taking anakinra.
- Withhold drug and notify physician for S&S of upper respiratory, skin, or other infection(s).